EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy

Molecular Vision

Volumn 18, Issue , 2012, Pages 290-308

  Mitra, Moutushy ^a,c   Kandalam, Mallikarjuna ^a   Harilal, Anju ^a   Verma, Rama Shenkar ^b   Krishnan, Uma Maheswari ^c   Swaminathan, Sethuraman ^c   Krishnakumar, Subramanian ^a  

^a Vision Research Foundation   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

^c SASTRA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; CD24 ANTIGEN; CD3 ANTIBODY; CELL MARKER; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; PERFORIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL INVASION; CELL ISOLATION; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFANT; LYMPHOCYTE ACTIVATION; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RETINOBLASTOMA;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD24; ANTIGENS, CD44; ANTIGENS, NEOPLASM; ATP-BINDING CASSETTE TRANSPORTERS; CELL ADHESION MOLECULES; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; INFANT; MALE; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PRIMARY CELL CULTURE; RETINAL NEOPLASMS; RETINOBLASTOMA; RNA, SMALL INTERFERING; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL;

EID: 84856804158     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005; 45:872-7.[PMID: 16027397]
2. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441:475-82.[PMID: 16598206]
3. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stemcell biology to cancer. Nat Rev Cancer 2003; 3:895-902.[PMID: 14737120]
4. Vercauteren SM, Sutherland HJ. CD133 (AC133) expression on AML cells and progenitors. Cytotherapy 2001; 3:449-59.[PMID: 11953029]
5. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63:5821-8.[PMID: 14522905]
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-8.[PMID: 12629218]
7. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65:5506-11.[PMID: 15994920]
8. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Conolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006; 103:11154-9.[PMID: 16849428]
9. Mohan A, Kandalam M, Ramkumar HL, Gopal L, Krishnakumar S. Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma. Br J Ophthalmol 2006; 90:889-93.[PMID: 16556617]
10. Silva AK, Yi H, Hayes SH, Seigel GM, Hackam AS. Lithium chloride regulates the proliferation of stem-like cells in retinoblastoma cell lines: a potential role for the canonical Wnt signaling pathway. Mol Vis 2010; 16:36-45.[PMID: 20069066]
11. Seigel GM, Hackam AS, Ganguly A, Mandell LM, Gonzalez- Fernandez F. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis 2007; 13:823-32.[PMID: 17615543]
12. Schmelzer E, Zhang L, Bruce A, Wauthier E, Ludlow J, Yao HL, Moss N, Melhem A, McClelland R, Turner W, Kulik M, Sherwood S, Tallheden T, Cheng N, Furth ME, Reid LM. Human hepatic stem cells from fetal and postnatal donors. J Exp Med 2007; 204:1973-87.[PMID: 17664288]
13. Tanaka M, Okabe M, Suzuki K, Kamiya Y, Tsukahara Y, Saito S, Miyajima A. Mouse hepatoblasts at distinct developmental stages are characterized by expression of EpCAM and DLK1: drastic change of EpCAM expression during liver development. Mech Dev 2009; 126:665-76.[PMID: 19527784]
14. Krishnakumar S, Mohan A, Mallikarjuna K, Venkatesan N, Biswas J, Shanmugam MP, Ren-Heidenreich L. EpCAM expression in retinoblastoma: a novel molecular target for therapy. Invest Ophthalmol Vis Sci 2004; 45:4247-50.[PMID: 15557427]
15. Mitra M, Kandalam M, Verma RS. UmaMaheswari K, Krishnakumar S. Mol Vis 2010; 16:828-42. [PMID: 20461151]
16. Ren-Heidenreich L, Davol PA, Kouttab NM, Elfenbein GJ, Lum LG. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model. Cancer 2004; 100:1095-103.[PMID: 14983507]
17. Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P, Slavin S. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Exp Hematol 2008; 36:997-1003.[PMID: 18495330]
18. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005; 10:1237-44.[PMID: 16213416]
19. Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jäger M, Ströhlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007; 13:3899-905.[PMID: 17606723]
20. Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P, Kimmig R, Baeuerle PA. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain EpCAM-/CD3-bispecific antibody construct. Cancer Res 2005; 65:2882-9.[PMID: 15805290]
21. Amann M, Brischwein K, Lutterbuese P, Parr L, Petersen L, Lorenczewski G, Krinner E, Bruckmeier S, Lippold S, Kischel R, Lutterbuese R, Kufer P, Baeuerle PA, Schlereth B. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res 2008; 68:143-51.[PMID: 18172306]
22. Krishnakumar S, Sundaram A, Abhyankar D, Krishnamurthy V, Shanmugam MP, Gopal L, Sharma T, Biswas J. Major histocompatibility antigens and antigen-processing molecules in retinoblastoma. Cancer 2004; 100:1059-69.[PMID: 14983503]
23. Strauss G, Gückel B, Wallwiener D, Moldenhauer G. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3. Clin Cancer Res 1999; 5:171-80.[PMID: 9918216]
24. Marmé A, Strauss G, Bastert G, Grischke EM, Moldenhauer G. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer 2002; 101:183-9.[PMID: 12209996]
25. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-8.[PMID: 12629218]
26. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67:1030-7.[PMID: 17283135]
27. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG. Highly purified CD44{thorn} prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25:1696-708.[PMID: 16449977]
28. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104:10158-63.[PMID: 17548814]
29. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4:33-45.[PMID: 12511867]
30. Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristiansen G. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005; 11:6574-81.[PMID: 16166435]
31. Balla MM, Vemuganti GK, Kannabiran C, Honavar SG, Murthy R. Phenotypic characterization of retinoblastoma for the presence of putative cancer stem-like cell markers by flow cytometry. Invest Ophthalmol Vis Sci 2009; 50:1506-14.[PMID: 19029022]
32. Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F. Cancer stem cell characteristics in retinoblastoma. Mol Vis 2005; 11:729-37.[PMID: 16179903]
33. Chaichana K, Zamora-Berridi G, Camara-Quintana J, Quiñones-Hinojosa A. Neurosphere assays: growth factors and hormone differences in tumor and nontumor studies. Stem Cells 2006; 24:2851-7.[PMID: 16945995]
34. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65:13-24.[PMID: 1707342]
35. Hofmann M, Rudy W, Zöller M, Tölg C, Ponta H, Herrlich P, Günthert U. CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 1991; 51:5292-7.[PMID: 1717145]
36. Rudy W, Hofmann M, Schwartz-Albiez R, Zöller M, Heider KH, Ponta H, Herrlich P. The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res 1993; 53:1262-8.[PMID: 8443806]
37. Reber S, Matzku S, Günthert U, Ponta H, Herrlich P, Zöller M. Retardation of metastatic tumor growth after immunization with metastasis-specific monoclonal antibodies. Int J Cancer 1990; 46:919-27.[PMID: 2228320]
38. Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, Herrlich P, Matzku S, Zöller M. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993; 177:443-55.[PMID: 8426113]
39. Penno MB, August JT, Baylin SB, Mabry M, Linnoila RI, Lee VS, Croteau D, Yang XL, Rosada C. Expression of CD44 in human lung tumors. Cancer Res 1994; 54:1381-7.[PMID: 7509720]
40. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434:843-50.[PMID: 15829953]
41. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998; 14:59-88.[PMID: 9891778]
42. Tell S, Yi H, Jockovich ME, Murray TG, Hackam AS. The Wnt signaling pathway has tumor suppressor properties in retinoblastoma. Biochem Biophys Res Commun 2006; 349:261-9.[PMID: 16930536]
43. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5:275-84.[PMID: 15803154]
44. Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunol Immunother 2007; 56:1637-44.[PMID: 17410361]
45. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006; 43:1129-43.[PMID: 16139892]
46. Salnikov AV, Groth A, Apel A, Kallifatidis G, Beckermann BM, Khamidjanov A, Ryschich E, Büchler MW, Herr I, Moldenhauer G. Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma. J Cell Mol Med 2009; 13:4023-33.[PMID: 20196789]
47. Kang SS, Allen PM. Priming in the presence of IL-10 results in direct enhancement of CD8+ T cell primary responses and inhibition of secondary responses. J Immunol 2005; 174:5382-9.[PMID: 15843536]
48. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29:117-29.[PMID: 11586292]